Pages that link to "Q66809426"
Jump to navigation
Jump to search
The following pages link to Mario Sznol (Q66809426):
Displaying 50 items.
- PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells (Q24606438) (← links)
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma (Q24607661) (← links)
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer (Q24633070) (← links)
- Nivolumab plus ipilimumab in advanced melanoma (Q27852310) (← links)
- Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy (Q28394869) (← links)
- Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications (Q28474843) (← links)
- Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015 (Q28553228) (← links)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma (Q29615443) (← links)
- Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma (Q33340438) (← links)
- Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors (Q33357008) (← links)
- A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia (Q33360707) (← links)
- A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer (Q33365226) (← links)
- Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies (Q33437008) (← links)
- Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers (Q33441115) (← links)
- Melanoma: a model for testing new agents in combination therapies (Q33863916) (← links)
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial (Q33926135) (← links)
- Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. (Q34049618) (← links)
- MicroRNA signatures differentiate melanoma subtypes (Q34182764) (← links)
- Programmed death ligand-1 expression in non-small cell lung cancer (Q34384255) (← links)
- Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor (Q34484174) (← links)
- A clinical development paradigm for cancer vaccines and related biologics (Q34596591) (← links)
- A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer (Q34805903) (← links)
- A phase 2 trial of dasatinib in advanced melanoma (Q35048145) (← links)
- Biology of advanced uveal melanoma and next steps for clinical therapeutics (Q35079709) (← links)
- Melanoma brain metastases: is it time to reassess the bias? (Q35214698) (← links)
- Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo (Q35235365) (← links)
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab (Q35289145) (← links)
- In vitro studies of dasatinib, its targets and predictors of sensitivity (Q35607192) (← links)
- The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization (Q35632517) (← links)
- Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma (Q35728471) (← links)
- Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites (Q35812429) (← links)
- Chitinase-like proteins in lung injury, repair, and metastasis (Q35984042) (← links)
- Plasma markers for identifying patients with metastatic melanoma (Q36152030) (← links)
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (Q36352827) (← links)
- Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma (Q36934332) (← links)
- Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas (Q37028299) (← links)
- Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer (Q37182719) (← links)
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma (Q37237228) (← links)
- A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye (Q37304878) (← links)
- C-Raf is associated with disease progression and cell proliferation in a subset of melanomas (Q37389958) (← links)
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (Q37409862) (← links)
- Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells (Q37509860) (← links)
- Betting on immunotherapy for melanoma (Q37579301) (← links)
- Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies (Q37809159) (← links)
- White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy (Q37843043) (← links)
- Molecular markers of response to treatment for melanoma (Q37856122) (← links)
- Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival (Q38019011) (← links)
- Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy (Q38237434) (← links)
- Advances in the systemic treatment of metastatic melanoma. (Q38245746) (← links)
- Therapeutic combinations of immune-modulating antibodies in melanoma and beyond (Q38475140) (← links)